Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA. 1987;257(22):3076–81. https://doi.org/10.1001/jama.257.22.3076.

Article  CAS  PubMed  Google Scholar 

Abarbanel J, Marcus EL. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology. 2007;69(3):436–40. https://doi.org/10.1016/j.urology.2006.11.019.

Article  PubMed  Google Scholar 

Yamamoto T, Sakakibara R, Uchiyama T, Liu Z, Ito T, Awa Y, et al. Neurological diseases that cause detrusor hyperactivity with impaired contractile function. Neurourol Urodyn. 2006;25(4):356–60. https://doi.org/10.1002/nau.20224.

Article  PubMed  Google Scholar 

Chancellor MB. The overactive bladder progression to underactive bladder hypothesis. Int Urol Nephrol. 2014;46(Suppl 1):S23–7. https://doi.org/10.1007/s11255-014-0778-y.

Article  PubMed  Google Scholar 

•• Mancini V, Tarcan T, Serati M, Wyndaele M, Carrieri G, Abrams P. Is coexistent overactive-underactive bladder (with or without detrusor overactivity and underactivity) a real clinical syndrome? ICI-RS 2019. Neurourol Urodyn. 2020;39(Suppl 3):S50–S9. https://doi.org/10.1002/nau.24311. A comprehensive review of the diagnosis and treatment of coexisting OAB and UAB syndrome, and a demonstration of multifactorial etiological hypotheses.

Article  PubMed  Google Scholar 

Griffiths DJ, McCracken PN, Harrison GM, Gormley EA, Moore KN. Urge incontinence and impaired detrusor contractility in the elderly. Neurourol Urodyn. 2002;21(2):126–31. https://doi.org/10.1002/nau.10042.

Article  PubMed  Google Scholar 

Lee Y-S, Lee HN, Cho WJ, Lee HS, Lee K-S. Detrusor overactivity with impaired contractility (DOIC) in the elderly: challenges in management. Curr Bladder Dysfunct Rep. 2015;10(3):278–87. https://doi.org/10.1007/s11884-015-0313-8.

Article  Google Scholar 

Resnick NM, Brandeis GH, Baumann MM, DuBeau CE, Yalla SV. Misdiagnosis of urinary incontinence in nursing home women: prevalence and a proposed solution. Neurourol Urodyn. 1996;15(6):599–618. https://doi.org/10.1002/(sici)1520-6777(1996)15:6<599::Aid-nau2>3.0.Co;2-a.

Yalla SV, Sullivan MP, Resnick NM. Update on detrusor hyperactivity with impaired contractility. Curr Bladder Dysfunct Rep. 2007;2(4):191–6. https://doi.org/10.1007/s11884-007-0019-7.

Article  Google Scholar 

Liu S, Chan L, Tse V. Clinical outcome in male patients with detrusor overactivity with impaired contractility. Int Neurourol J. 2014;18(3):133–7. https://doi.org/10.5213/inj.2014.18.3.133.

Article  PubMed  PubMed Central  Google Scholar 

Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63. https://doi.org/10.1016/j.juro.2012.09.079.

Article  PubMed  Google Scholar 

Chung SD, Chang HC, Chiu B, Liao CH, Kuo HC. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia. Neurourol Urodyn. 2011;30:568–71. https://doi.org/10.1002/nau.20923.

Article  CAS  PubMed  Google Scholar 

Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011;65:487–507. https://doi.org/10.1111/j.1742-1241.2010.02611.x.

Article  CAS  PubMed  Google Scholar 

Miller KL, DuBeau CE, Bergmann MA, et al. Dose titration key to oxybutynin efficacy for geriatric incontinence, even for DHIC [Abstract]. Neurourol Urodyn. 2000;19:538–9.

Google Scholar 

Kim M, Jung JH, Park J, Son H, Jeong SJ, Oh SJ, Cho SY. Seoul National University Experts of Urodynamics Leading Study Group. Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:205–10. https://doi.org/10.1016/j.parkreldis.2014.12.003.

Article  PubMed  Google Scholar 

•• Chiang CH, Chen SF, Kuo HC. Video-urodynamic characteristics of lower urinary tract dysfunctions in patients with chronic brain disorders. Neurourol Urodyn. 2022;41:255–63. https://doi.org/10.1002/nau.24806. A real-world investigations in VUDS characteristics of patients with chronic brain disorders. High prevalence of DO and functional BOO were noted, and the rate of DHIC was 16.6%.

Article  PubMed  Google Scholar 

• Dmochowski RR, Thai S, Iglay K, Enemchukwu E, Tee S, Varano S, Girman C, Radican L, Mudd PN Jr, Poole C. Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol Urodyn. 2021;40:28–37. https://doi.org/10.1002/nau.24536. A recent meta-analysis suggested tht anticholinergic use for over 3 months increased the risk of dementia. The risk and benefit of prescribing anticholinergics should be carefully evaluated in patients with OAB.

Article  PubMed  Google Scholar 

Chapple CR, Amarenco G, Lopez Aramburu MA, Everaert K, Liehne J, Lucas M, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32(8):1116–22. https://doi.org/10.1002/nau.22373.

Article  CAS  PubMed  Google Scholar 

Thiagamoorthy G, Kotes S, Zacche M, Cardozo L. The efficacy and tolerability of mirabegron, a beta3-adrenoceptor agonist, in patients with symptoms of overactive bladder. Ther Adv Urol. 2016;8(1):38–46. https://doi.org/10.1177/1756287215614237.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee CL, Kuo HC. Efficacy and safety of mirabegron, a beta(3) -adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. Low Urin Tract Symptoms. 2019;11(2):O93–O7. https://doi.org/10.1111/luts.12224.

Article  CAS  PubMed  Google Scholar 

Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–63. https://doi.org/10.1097/JU.0000000000000309.

Article  PubMed  Google Scholar 

Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology. 2004;63(5):868–72. https://doi.org/10.1016/j.urology.2003.12.007.

Article  PubMed  Google Scholar 

Kuo YC, Kuo HC. Botulinum toxin injection for lower urinary tract dysfunction. Int J Urol. 2013;20(1):40–55. https://doi.org/10.1111/j.1442-2042.2012.03035.x.

Article  CAS  PubMed  Google Scholar 

Wang CC, Lee CL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility. Toxins (Basel). 2016;8(3) https://doi.org/10.3390/toxins8030082.

Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Sturzebecher B, Miller K, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol. 2005;48(6):984–90. https://doi.org/10.1016/j.eururo.2005.06.021.

Article  PubMed  Google Scholar 

Bemelmans BL, Mundy AR, Craggs MD. Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction. Eur Urol. 1999;36(2):81–91. https://doi.org/10.1159/000067976.

Article  CAS  PubMed  Google Scholar 

Heesakkers JPFA, Blok B. Electrical stimulation and neuromodulation in storage and emptying failure. In: Partin A, Peters C, Kavoussi L, Dmochowski R, editors. Campbell Walsh Wein Urology. 12th ed. Elsevier; 2020.

Google Scholar 

Hennessey DB, Hoag N, Gani J. Sacral neuromodulation for detrusor hyperactivity with impaired contractility. Neurourol Urodyn. 2017;36(8):2117–22. https://doi.org/10.1002/nau.23255.

Article  PubMed  Google Scholar 

Yoshida S, Orimoto N, Tsukihara H, Noma T, Hakozaki A, Sasaki E. TAC-302 promotes neurite outgrowth of isolated peripheral neurons and prevents bladder denervation related bladder dysfunctions following bladder outlet obstruction in rats. Neurourol Urodyn. 2018;37(2):681–9. https://doi.org/10.1002/nau.23375.

Article  CAS  PubMed  Google Scholar 

Yoshida S, Noma T, Miyoshi K, Tsukihara H, Orimoto N, Hakozaki A, et al. Therapeutic effect of TAC-302, a cyclohexenoic fatty alcohol derivative, on bladder denervation-related storage and voiding dysfunctions in rats. Neurourol Urodyn. 2018;37(7):2106–13. https://doi.org/10.1002/nau.23571.

Article  CAS  PubMed  Google Scholar 

•• Yoshida M, Gotoh M, Yokoyama O, Kakizaki H, Yamanishi T, Yamaguchi O. Efficacy of TAC-302 for patients with detrusor underactivity and overactive bladder: a randomized, double-blind, placebo-controlled phase 2 study. World J Urol. 2022;40(11):2799–805. https://doi.org/10.1007/s00345-022-04163-4. A novel drug TAC-302 significantly improved BCI for males and bladder voiding efficiency in both sexes without increasing the risk of adeverse events. TAC-302 may benefit patients with DU.

Article  CAS  PubMed  PubMed Central  Google Scholar